Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18441600 | TREATMENT OF NEURODEGENERATIVE DISEASE WITH SODIUM CHLORITE | February 2024 | June 2024 | Allow | 4 | 0 | 0 | Yes | No |
| 18441611 | TREATMENT OF NEURODEGENERATIVE DISEASE WITH SODIUM CHLORITE | February 2024 | July 2024 | Allow | 5 | 0 | 0 | Yes | No |
| 18441621 | TREATMENT OF NEURODEGENERATIVE DISEASE WITH SODIUM CHLORITE | February 2024 | July 2024 | Allow | 5 | 0 | 0 | Yes | No |
| 18441597 | TREATMENT OF NEURODEGENERATIVE DISEASE WITH SODIUM CHLORITE | February 2024 | August 2024 | Allow | 6 | 0 | 0 | Yes | No |
| 18488967 | 1-(3-CHLOROBENZYLIDENEAMINO)-5,5-DIPHENYLIMIDAZOLIDINE-2,4-DIONE AS AN ANTIMICROBIAL COMPOUND | October 2023 | January 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18377606 | HMOX1 INDUCERS | October 2023 | April 2024 | Allow | 6 | 1 | 1 | Yes | No |
| 18549374 | Deuterated Empathogens | September 2023 | May 2024 | Allow | 8 | 1 | 1 | Yes | No |
| 18260853 | QUATERNARY TRYPTAMINES AND THEIR THERAPEUTIC USES | July 2023 | February 2024 | Allow | 7 | 0 | 1 | Yes | No |
| 18210555 | PROTEASE INHIBITORS AS ANTIVIRALS | June 2023 | January 2024 | Allow | 7 | 0 | 1 | Yes | No |
| 18210526 | METHOD FOR TREATING ANXIETY DISORDERS, HEADACHE DISORDERS, AND EATING DISORDERS WITH PSILOCYBIN | June 2023 | August 2023 | Allow | 2 | 0 | 0 | Yes | No |
| 18208017 | COMPOSITIONS COMPRISING CANNABINOIDS AND METHODS OF USE | June 2023 | February 2024 | Allow | 9 | 1 | 0 | Yes | No |
| 18137094 | EXTRACTION OF ABSCISIC FROM STRAWBERRIES | April 2023 | May 2024 | Abandon | 12 | 2 | 1 | No | No |
| 18299701 | TREATMENT OF SEIZURE DISORDERS | April 2023 | May 2024 | Allow | 13 | 4 | 0 | Yes | Yes |
| 18099279 | PANTOTHENAMIDE ANALOGUES | January 2023 | July 2023 | Allow | 6 | 0 | 1 | Yes | No |
| 18095199 | TREATMENT OF NEURODEGENERATIVE DISEASE WITH SODIUM CHLORITE | January 2023 | November 2023 | Allow | 10 | 3 | 1 | Yes | No |
| 18095205 | TREATMENT OF NEURODEGENERATIVE DISEASE WITH SODIUM CHLORITE | January 2023 | November 2023 | Allow | 10 | 3 | 0 | Yes | No |
| 18095202 | TREATMENT OF NEURODEGENERATIVE DISEASE WITH SODIUM CHLORITE | January 2023 | November 2023 | Allow | 10 | 3 | 0 | Yes | No |
| 18083824 | COMPOSITIONS COMPRISING CANNABINOIDS AND METHODS OF USE | December 2022 | March 2023 | Allow | 2 | 0 | 0 | Yes | No |
| 18077876 | METHOD FOR TREATING ANXIETY DISORDERS, HEADACHE DISORDERS, AND EATING DISORDERS WITH PSILOCYBIN | December 2022 | March 2023 | Allow | 3 | 0 | 0 | Yes | No |
| 17256848 | DERIVATIZED BENZIMIDAZOLE COMPOUNDS, THEIR SALTS, THEIR COMPLEXES, THEIR PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USING THEM FOR ANTIGERIATRIC ACTIONS | November 2022 | September 2023 | Allow | 33 | 1 | 1 | Yes | No |
| 17975127 | ENANTIOMERIC RATIOS OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE AND RELATED METABOLITES AND USES THEREOF | October 2022 | March 2024 | Abandon | 16 | 2 | 1 | Yes | No |
| 17953819 | Pharmaceutical Composition Comprising Compound Capable of Penetrating Blood-Brain Barrier as Effective Ingredient for Preventing or Treating Brain Cancer | September 2022 | April 2024 | Allow | 19 | 1 | 0 | No | No |
| 17953867 | Pharmaceutical Composition Comprising Compound Capable of Penetrating Blood-Brain Barrier as Effective Ingredient for Preventing or Treating Brain Cancer | September 2022 | April 2024 | Allow | 19 | 1 | 0 | No | No |
| 17946508 | NITRILATED PSILOCYBIN DERIVATIVES AND METHODS OF USING | September 2022 | December 2023 | Allow | 15 | 2 | 1 | Yes | No |
| 17940950 | Methods of Treating Psychological and Brain Disorders | September 2022 | April 2024 | Abandon | 20 | 2 | 1 | No | No |
| 17823489 | TREATMENT OF NEURODEGENERATIVE DISEASE WITH SODIUM CHLORITE | August 2022 | November 2023 | Allow | 15 | 3 | 1 | Yes | No |
| 17896774 | METHOD OF TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) | August 2022 | June 2024 | Allow | 22 | 1 | 1 | Yes | No |
| 17820183 | PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | August 2022 | December 2023 | Allow | 16 | 1 | 0 | Yes | No |
| 17818836 | METABOLISM ENHANCING COMPOSITIONS | August 2022 | October 2023 | Allow | 15 | 0 | 1 | Yes | No |
| 17883210 | MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS | August 2022 | December 2023 | Allow | 17 | 0 | 1 | No | No |
| 17868106 | METHODS OF TREATING RESPIRATORY DISORDERS | July 2022 | April 2024 | Abandon | 21 | 0 | 1 | No | No |
| 17847860 | GAMMA-HYDROXYBUTYRATE SALTS FOR THE TREATMENT OF PSYCHOLOGICAL DISORDERS | June 2022 | October 2023 | Allow | 16 | 0 | 1 | Yes | No |
| 17834390 | GAMMA-HYDROXYBUTYRATE SALTS FOR THE TREATMENT OF LEARNING DISORDERS | June 2022 | September 2023 | Allow | 15 | 0 | 1 | Yes | No |
| 17805643 | METHODS AND COMPOSITIONS INCLUDING PROTOCATECHUIC ACID CRYSTALS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS | June 2022 | August 2023 | Allow | 14 | 2 | 0 | Yes | Yes |
| 17748098 | METHODS OF TREATMENT OF PARTIAL ONSET SEIZURES USING ESLICARBAZEPINE ACETATE | May 2022 | April 2024 | Abandon | 23 | 1 | 0 | Yes | No |
| 17746625 | METHODS OF TREATING HYPERTRIGLYCERIDEMIA | May 2022 | May 2024 | Abandon | 24 | 1 | 0 | No | No |
| 17745823 | SUBLINGUAL OR BUCCAL ADMINISTRATION OF DIM FOR TREATMENT OF SKIN DISEASES | May 2022 | October 2024 | Abandon | 29 | 1 | 0 | No | No |
| 17743653 | CANNABIDIOL-TYPE CANNABINOID COMPOUND | May 2022 | October 2022 | Allow | 5 | 0 | 1 | Yes | No |
| 17741146 | PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND AN AURORA KINASE INHIBITOR AND METHODS OF USE THEREOF | May 2022 | August 2023 | Allow | 16 | 0 | 0 | Yes | No |
| 17661116 | NOVEL LEVOTHYROXINE FORMULATIONS FOR ORAL USE | April 2022 | August 2023 | Allow | 16 | 0 | 0 | Yes | No |
| 17660479 | METHODS AND COMPOSITIONS FOR IMPROVING SLEEP | April 2022 | August 2023 | Allow | 16 | 0 | 0 | Yes | No |
| 17718819 | METHOD OF TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) | April 2022 | June 2022 | Allow | 2 | 0 | 0 | Yes | No |
| 17707542 | COMPOSITIONS COMPRISING CANNABINOIDS AND METHODS OF USE | March 2022 | November 2022 | Allow | 8 | 1 | 1 | Yes | No |
| 17655646 | SMALL MOLECULE TRAIL GENE INDUCTION BY NORMAL AND TUMOR CELLS AS AN ANTICANCER THERAPY | March 2022 | October 2023 | Allow | 19 | 0 | 1 | Yes | No |
| 17691448 | TREATMENT OF ADHD | March 2022 | April 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17652642 | COMPOSITIONS COMPRISING PROTOCATECHUIC ACID AND METHODS OF USE | February 2022 | September 2024 | Abandon | 30 | 4 | 1 | No | Yes |
| 17651879 | TREATMENT OF NF-KB-MEDIATED DISEASE | February 2022 | January 2024 | Abandon | 23 | 3 | 0 | No | No |
| 17586657 | AUTOIMMUNE DISORDER TREATMENT USING RXR AGONISTS | January 2022 | June 2023 | Allow | 17 | 3 | 0 | No | No |
| 17573979 | HETEROCYCLE-SUBSTITUTED BICYCLIC AZOLE PESTICIDES | January 2022 | February 2024 | Allow | 25 | 1 | 1 | Yes | No |
| 17568560 | Compositions and Methods for Treating Metabolic Disorders | January 2022 | March 2024 | Abandon | 26 | 0 | 1 | No | No |
| 17560035 | AUTOIMMUNE DISORDER TREATMENT USING RXR AGONISTS | December 2021 | October 2022 | Allow | 10 | 1 | 1 | No | No |
| 17540962 | METHOD FOR TREATING ANXIETY DISORDERS, HEADACHE DISORDERS, AND EATING DISORDERS WITH PSILOCYBIN | December 2021 | September 2022 | Allow | 9 | 1 | 0 | Yes | No |
| 17456617 | NOVEL COMBINATIONS OF A H3 ANTAGONIST AND A NORADRENALINE REUPTAKE INHIBITOR, AND THE THERAPEUTICAL USES THEREOF | November 2021 | December 2023 | Allow | 24 | 0 | 1 | Yes | No |
| 17532646 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | November 2021 | June 2022 | Allow | 6 | 0 | 1 | Yes | No |
| 17533061 | METHODS AND COMPOSITIONS FOR TREATING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE | November 2021 | March 2024 | Abandon | 27 | 3 | 1 | Yes | No |
| 17527440 | Compositions Comprising Oxo-Derivatives of Fatty Acids and Methods of Making and Using Same | November 2021 | February 2024 | Allow | 27 | 0 | 1 | Yes | No |
| 17526816 | REAGENTS AND METHODS FOR ESTERIFICATION | November 2021 | June 2024 | Allow | 31 | 1 | 1 | Yes | No |
| 17453432 | METHODS AND COMPOSITIONS INCLUDING PROTOCATECHUIC ACID CRYSTALS FOR THE TREATMENT OF CONDITIONS CAUSED BY AN ENVELOPED VIRUS | November 2021 | June 2024 | Allow | 32 | 4 | 1 | Yes | Yes |
| 17501692 | Compositions and Methods for Treating Patients Suffering from Glioma or Leukemia | October 2021 | September 2023 | Allow | 23 | 1 | 0 | Yes | No |
| 17496532 | ANTAGONISTS OF CB1 RECEPTOR | October 2021 | January 2024 | Abandon | 28 | 0 | 1 | No | No |
| 17488966 | DIROFILARIA VOLATILE ORGANIC COMPOUND SIGNATURES AND USES THEREOF | September 2021 | August 2022 | Allow | 11 | 0 | 1 | Yes | No |
| 17489244 | COMPOUNDS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH HUMAN PAPILLOMAVIRUS | September 2021 | April 2024 | Allow | 31 | 1 | 0 | No | No |
| 17477444 | COMPOSITIONS AND METHODS FOR TREATING NEUROPSYCHIATRIC DISORDERS | September 2021 | December 2022 | Allow | 15 | 2 | 1 | Yes | No |
| 17477415 | COMPOSITIONS AND METHODS FOR TREATING NEUROPSYCHIATRIC DISORDERS | September 2021 | August 2022 | Allow | 11 | 2 | 1 | Yes | No |
| 17470436 | COMPOSITIONS AND TREATMENTS FOR MICROBIAL PERSISTER CELLS | September 2021 | May 2024 | Abandon | 33 | 7 | 1 | Yes | No |
| 17458976 | Methods and Compositions for Pest Control | August 2021 | October 2023 | Abandon | 26 | 1 | 0 | No | No |
| 17407689 | USE OF HOMOHARRINGTONINE IN PREPARATION OF BETACORONAVIRUS REPLICATION INHIBITOR IN HUMAN | August 2021 | August 2023 | Allow | 24 | 4 | 1 | Yes | No |
| 17377898 | CONTROLLED RELEASE STERILE INJECTABLE ARIPIPRAZOLE FORMULATION AND METHOD | July 2021 | May 2024 | Abandon | 34 | 1 | 1 | No | No |
| 17373284 | USE AND METHOD OF L-ASPARTIC ACID beta-HYDROXAMATE IN PREPARING DRUGS FOR INHIBITING CHOROIDAL NEOVASCULARIZATION | July 2021 | March 2023 | Allow | 20 | 0 | 0 | Yes | No |
| 17372272 | Inhibition of Acetyl-CoA Metabolism for Treatment and Prevention of Immune System Diseases and Disorders | July 2021 | November 2023 | Abandon | 28 | 0 | 1 | No | No |
| 17418871 | PANTOTHENAMIDE ANALOGUES | June 2021 | September 2022 | Allow | 15 | 0 | 1 | Yes | No |
| 17419101 | ANTI-HELICOBACTER FOOD COMPOSITION COMPRISING BETA-CARYOPHYLLENE | June 2021 | November 2022 | Abandon | 16 | 2 | 0 | No | No |
| 17358471 | METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | June 2021 | March 2024 | Allow | 32 | 1 | 0 | No | No |
| 17330182 | MODULATING EXPRESSION LEVEL OF A GENE ENCODING AN APURINIC/APYRIMIDINIC ENDODEOXYRIBONUCLEASE PROTEIN BY TREATING A HUMAN SUBJECT WITH A NITROXIDE | May 2021 | September 2022 | Allow | 15 | 2 | 1 | No | No |
| 17327465 | TREATMENT OF TOURETTE'S SYNDROME WITH ECOPIPAM | May 2021 | April 2022 | Abandon | 11 | 1 | 0 | No | No |
| 17306458 | METHODS OF TREATING EOSINOPHILIC ESOPHAGITIS | May 2021 | November 2022 | Allow | 18 | 2 | 1 | Yes | No |
| 17244337 | MONOLITHIC TABLETS BASED ON CARBOXYL POLYMERIC COMPLEXES FOR CONTROLLED DRUG RELEASE | April 2021 | May 2024 | Abandon | 36 | 1 | 1 | No | No |
| 17228590 | METHODS OF TREATING RBP4 RELATED DISEASES WITH TRIAZOLOPYRIDINES | April 2021 | December 2023 | Allow | 33 | 1 | 1 | No | No |
| 17275608 | NEAR-INFRARED NERVE-SPARING BENZO[C]PHENOXAZINE FLUOROPHORES | March 2021 | February 2024 | Allow | 35 | 0 | 0 | No | No |
| 17188850 | Long Term Treatment of HIV-Infection With TMC278 | March 2021 | October 2023 | Abandon | 31 | 1 | 0 | Yes | No |
| 17166560 | 7-BENZYL-4-(METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[3,4-E]PYRIMIDIN-5 (1H)-ONE, SALTS THEREOF AND METHODS OF USING THE SAME IN COMBINATION THERAPY | February 2021 | March 2024 | Abandon | 37 | 2 | 0 | No | No |
| 17264798 | New use of carbamate � phenylethanolamine analogues for enhancing intracellular clearance of LDL cholesterol and for combining therapy with statins to enhance the efficacy and reduce adverse effects | January 2021 | July 2023 | Abandon | 30 | 1 | 1 | No | No |
| 17147867 | PYRVINIUM PAMOATE THERAPIES AND METHODS OF USE | January 2021 | January 2024 | Abandon | 36 | 0 | 1 | No | No |
| 17112282 | 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-C]PYRIDINES AND THEIR ANTI-INFLAMMATORY USES THEREOF | December 2020 | February 2023 | Allow | 26 | 0 | 0 | Yes | No |
| 17103455 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | November 2020 | April 2023 | Allow | 29 | 0 | 1 | Yes | No |
| 17054686 | NOVEL MODULATOR OF METABOTROPIC AND IONOTROPIC TRANSMEMBRANE RECEPTORS AND USE THEREOF | November 2020 | April 2022 | Allow | 18 | 0 | 1 | Yes | No |
| 17088063 | ESTER NITRATES DERIVATIVES OF AROMATIC ALDEHYDES WITH MULTIPLE PHARMALOGIC PROPERTIES TO TREAT SICKLE CELL DISEASE | November 2020 | January 2024 | Abandon | 38 | 1 | 0 | Yes | No |
| 17083569 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | October 2020 | December 2023 | Abandon | 37 | 0 | 1 | No | No |
| 17076379 | TREATMENT METHOD FOR CORONAVIRUS INFECTION | October 2020 | November 2023 | Abandon | 37 | 3 | 0 | Yes | No |
| 17072511 | USE OF (S)-3-AMINO-4-(DIFLUOROMETHYLENYL) CYCLOPENT-1-ENE-1-CARBOXYLIC ACID AND RELATED COMPOUNDS, (1S,3S)-3-AMINO-4-(DIFLUOROMETHYLIDENE) CYCLOPENTANE-1-CARBOXYLIC ACID AND VIGABATRIN IN THE TREATMENT OF DEVELOPMENTAL DISORDERS | October 2020 | January 2023 | Allow | 27 | 0 | 0 | No | No |
| 17062982 | DIACYLGLYCEROL ACYL TRANSFERASE 2 INHIBITOR | October 2020 | May 2022 | Allow | 20 | 0 | 0 | Yes | No |
| 17025130 | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | September 2020 | October 2022 | Abandon | 25 | 3 | 1 | Yes | No |
| 16981430 | SOLID FORM OF DIHYDROPYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | September 2020 | June 2022 | Allow | 21 | 0 | 1 | Yes | No |
| 17018221 | ALKYNYL PYRIDINE PROLYL HYDROXYLASE INHIBITOR, AND PREPARATION METHOD AND MEDICAL USE THEREOF | September 2020 | February 2023 | Allow | 29 | 0 | 0 | No | No |
| 17010153 | COMPOSITION FOR PROMOTING SKELETAL MUSCLE ACTIVITY VIA INDUCTION OF MITOCHONDRIAL BIOGENESIS COMPRISING OF AZELAIC ACID AS AN ACTIVE INGREDIENT | September 2020 | November 2023 | Allow | 39 | 4 | 1 | Yes | No |
| 17001127 | METHODS OF TREATING TESTOSTERONE DEFICIENCY | August 2020 | May 2023 | Abandon | 32 | 1 | 0 | No | No |
| 17000301 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | August 2020 | July 2022 | Allow | 23 | 0 | 1 | Yes | No |
| 16947759 | METHODS OF TREATING SARS COV-2 VIRUS WITH PROTOCATECHUIC ACID | August 2020 | February 2021 | Allow | 6 | 1 | 0 | Yes | No |
| 16987609 | ESTER NITRATES DERIVATIVES OF AROMATIC ALDEHYDES WITH MULTIPLE PHARMALOGIC PROPERTIES TO TREAT SICKLE CELL DISEASE | August 2020 | October 2020 | Allow | 3 | 1 | 1 | No | No |
| 16943871 | COMBINATION THERAPY FOR THE TREATMENT OF MASTOCYTOSIS | July 2020 | May 2024 | Allow | 46 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHONG, YONG SOO.
With a 47.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 23.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner CHONG, YONG SOO works in Art Unit 1627 and has examined 889 patent applications in our dataset. With an allowance rate of 42.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 36 months.
Examiner CHONG, YONG SOO's allowance rate of 42.5% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by CHONG, YONG SOO receive 2.20 office actions before reaching final disposition. This places the examiner in the 75% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by CHONG, YONG SOO is 36 months. This places the examiner in the 16% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +56.9% benefit to allowance rate for applications examined by CHONG, YONG SOO. This interview benefit is in the 96% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 9.5% of applications are subsequently allowed. This success rate is in the 2% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 20.2% of cases where such amendments are filed. This entry rate is in the 17% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 76.6% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 59% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 55.6% of appeals filed. This is in the 23% percentile among all examiners. Of these withdrawals, 42.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 43.6% are granted (fully or in part). This grant rate is in the 47% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 1.5% of allowed cases (in the 73% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.1% of allowed cases (in the 57% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.